利用序列对称分析筛查真实世界数据中的意外药物获益
研究基于丹麦1996-2022年处方与患者登记数据,采用序列对称分析和病例交叉设计系统筛查药物-结局关联,发现7795个药物-诊断和5088个药物-药物组合具有预防性关联,排名前100中11个药物-诊断和2个药物-药物关联为潜在未知附带获益。
要点
- 序列对称分析联合病例交叉设计可系统筛查潜在附带药物获益。
- 排名前100关联中仅少数为潜在未知附带获益,需进一步验证。
核心结论
- 假设自由筛查可行,序列对称分析联合病例交叉设计能识别潜在附带药物获益。
研究设计与样本
- 基于丹麦国家处方登记和患者登记1996-2022年数据的观察性筛查研究。
- 采用序列对称分析(暴露锚定自身对照设计)比较暴露前后对称窗口内结局数。
- 用病例交叉设计验证关联方向性和稳健性,并按假设因果下避免结局数排序。
主要发现
- 序列对称分析和病例交叉设计均显示预防性关联的有7795个药物-诊断组合和5088个药物-药物组合。
- 排名前100关联经人工审查,11个药物-诊断和2个药物-药物关联为潜在未知附带获益。
- notable findings包括选择性5-羟色胺再摄取抑制剂与某些心血管结局风险降低相关。
- 抗胆碱酯酶药与谵妄诊断减少相关,孕激素与肥胖风险降低相关。
临床怎么用
- 该筛查方法可为药物重定位提供假设生成,但发现需进一步验证研究确认。
局限性
- 研究结论指出需进一步验证研究确认发现并探索临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this is to test the feasibility of identifying unsuspected, previously unknown drug-outcome associations, that is, collateral drug benefits (CDBs), through a systematic screening analysis of real-world health-care databases. Ultimately, such screening could lead to drug repurposing. METHODS: We analysed data from the Danish National Prescription Registry and the Danish Patient Registry, covering 1996-2022. The study employed the sequence symmetry analysis (SSA), an exposure-anchored self-controlled design that compares the number of clinical outcomes in symmetrical windows before and after the exposure drug initiation. To verify the directionality and robustness of these associations, we incorporated the case-crossover (CCO) design, another self-controlled design. The obtained associations were ranked according to the hypothetical number of averted outcomes, if a causal effect could be assumed. RESULTS: The analysis included 1.3 billion prescriptions and 260 million diagnosis records, resulting in 27 820 976 drug-diagnosis combinations and 7 920 323 drug-drug combinations. Preventive associations in both the SSA and CCO were found in 7795 drug-diagnosis and 5088 drug-drug combinations. A manual review of the highest ranked 100 associations resulted in 11 drug-diagnosis and 2 drug-drug associations as potential unknown CDBs. Notable findings included selective serotonin reuptake inhibitors linked to a lower risk of certain cardiovascular outcomes, anticholinesterases associated with fewer delirium diagnoses and progestogens associated with a reduced risk of obesity. CONCLUSIONS: The study confirms that hypothesis-free screening is feasible and that combining sequence symmetry analysis and case-crossover designs can identify potential collateral drug benefits. Further validation studies are required to confirm these findings and explore their clinical implications.
引用
- Rahbek MT, Lund LC, Hallas J, et al. Screening real-world data for evidence of unsuspected drug benefits: An application of the sequence symmetry analysis. Br J Clin Pharmacol. 2025. PMID: 41420263. doi:10.1002/bcp.70427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。